NCT03137784 - Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma | Biotech Hunter

Enrollment

148

Participants

Timeline

Start Date

May 4, 2017

Primary Completion Date

December 29, 2017

Study Completion Date

December 29, 2017

Conditions

Asthma

Interventions

DRUG

NVA237 (glycopyrronium bromide)

In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose

DRUG

Placebo

In each treatment arm, patient will receive placebo

Trial Locations (21)

2800

Novartis Investigative Site, Mechelen

3500

Novartis Investigative Site, Hasselt

5100

Novartis Investigative Site, Erpent

10119

Novartis Investigative Site, Berlin

22927

Novartis Investigative Site, Großhansdorf

23552

Novartis Investigative Site, Lübeck

27607

Novartis Investigative Site, Raleigh

60596

Novartis Investigative Site, Frankfurt

63141

Novartis Investigative Site, St Louis

65187

Novartis Investigative Site, Wiesbaden

79903

Novartis Investigative Site, El Paso

97504

Novartis Investigative Site, Medford

02747

Novartis Investigative Site, North Dartmouth

08558

Novartis Investigative Site, Skillman

169-0073

Novartis Investigative Site, Shinjuku-ku

171-0014

Novartis Investigative Site, Toshima-ku

LV-5417

Novartis Investigative Site, Daugavpils

LV 1002

Novartis Investigative Site, Riga

LV-1038

Novartis Investigative Site, Riga

LT-92231

Novartis Investigative Site, Klaipėda

LT-92288

Novartis Investigative Site, Klaipėda